aTYR PHARMA (ATYR) Capital Expenditures Growth (1y) (2015 - 2026)
Powered by 
Analysis
aTYR PHARMA (ATYR) Capital Expenditures Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 39.02% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 30.84% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | -22.99% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 9.68% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 1,133.33% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 142.64% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 53.76% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | 711.11% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 711.11% |
| Dec 31, 2025 | 24.00% |
| Sep 30, 2025 | 146.67% |
| Jun 30, 2025 | 12.50% |
| Dec 31, 2024 | 47.06% |
| Sep 30, 2024 | -97.31% |
| Jun 30, 2024 | -99.67% |
| Mar 31, 2024 | -98.64% |
| Dec 31, 2023 | -98.48% |
| Sep 30, 2023 | 30.75% |
| Jun 30, 2023 | 4,418.87% |
| Mar 31, 2023 | 2,797.67% |
| Dec 31, 2022 | 6,116.67% |
| Sep 30, 2022 | 598.36% |
| Jun 30, 2022 | -44.79% |
| Mar 31, 2022 | 152.94% |
| Dec 31, 2021 | 260.00% |
| Sep 30, 2021 | 408.33% |
| Jun 30, 2021 | 405.26% |
| Mar 31, 2021 | -89.76% |